Why I Went Into Radiation Oncology

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

A phase 2 trial demonstrated a median overall survival of 43.5 months at 60 Gy compared with 22.5 months at 45 Gy in patients with limited-stage SCLC.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Mike Lattanzi, MD;Damian N. Sorce, MD

THIO Plus Cemiplimab Associated with Prolonged OS in ICI-Resistant NSCLC

Experts weigh in on the practical applications of PSMA PET imaging

Gina Mauro

Exploring Burnout Causes and Management in Oncologic Practice

THIO with cemiplimab is active and well-tolerated in patients with advanced non–small cell lung cancer resistant to immune checkpoint inhibitors in second- and third-line settings.

Professor of Pharmacology, Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.

Eric P. Winer, MD

June 2nd 2025

Olanzapine May Prevent Radiation-Induced Nausea and Vomiting

Professor of Pharmacology, Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.

The addition of olanzapine to antiemetics might alleviate insomnia, appetite loss, anxiety, and depression in those receiving concurrent chemoradiation.

Roman Fabbricatore

ctDNA Analysis Shows Durvalumab/CRT Reduced Progression in Advanced Cervical Cancer

The addition of olanzapine to antiemetics might alleviate insomnia, appetite loss, anxiety, and depression in those receiving concurrent chemoradiation.

Ashley Chan

Twice Daily, Hyperfractionated Thoracic Radiotherapy Effective at 60 Gy in SCLC

The risk of progression was reduced with the use of durvalumab/CRT for advanced cervical cancer, according to an exploratory ctDNA analysis.

Related Content

$Twice Daily, Hyperfractionated Thoracic Radiotherapy Effective at 60 Gy in SCLC$

Tim Cortese

June 6th 2025

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

A phase 2 trial demonstrated a median overall survival of 43.5 months at 60 Gy compared with 22.5 months at 45 Gy in patients with limited-stage SCLC.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Mike Lattanzi, MD;Damian N. Sorce, MD

THIO Plus Cemiplimab Associated with Prolonged OS in ICI-Resistant NSCLC

Experts weigh in on the practical applications of PSMA PET imaging

Gina Mauro

Exploring Burnout Causes and Management in Oncologic Practice

THIO with cemiplimab is active and well-tolerated in patients with advanced non–small cell lung cancer resistant to immune checkpoint inhibitors in second- and third-line settings.

Eric P. Winer, MD

June 2nd 2025

Olanzapine May Prevent Radiation-Induced Nausea and Vomiting

Professor of Pharmacology, Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.

Roman Fabbricatore

ctDNA Analysis Shows Durvalumab/CRT Reduced Progression in Advanced Cervical Cancer

The addition of olanzapine to antiemetics might alleviate insomnia, appetite loss, anxiety, and depression in those receiving concurrent chemoradiation.

Ashley Chan